Celebrex Heart Risk Findings In Cancer Study Deals Blow To COX-2s
This article was originally published in The Tan Sheet
Executive Summary
Broad regulatory investigations into the COX-2 class could quickly extend to all NSAIDs
You may also be interested in...
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer is working to supply the Justice Department and several state attorneys general with materials related to the company's handling of marketing and safety issues associated with Celebrex and Bextra
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer is working to supply the Justice Department and several state attorneys general with materials related to the company's handling of marketing and safety issues associated with Celebrex and Bextra
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer is working to supply the Justice Department and several state attorneys general with materials related to the company's handling of marketing and safety issues associated with Celebrex and Bextra